WaveMan · Company
ADGM · Adagio Medical Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ADGM Adagio Medical (ADGM) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0002006986
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$0
FY Dec 2024$399.0K
FY Dec 2023n/a
Jun 2026$0
Mar 2026$0
Dec 2025$0
Sep 2025$0
Jun 2025$0
Mar 2025$0
Jun 2024$254.0K
Mar 2024$26.0K
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024-2,257%
Mar 2024n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
-$16.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025-$19.4M
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026-$5.3M
Mar 2026-$4.1M
Dec 2025-$3.6M
Sep 2025-$3.5M
Jun 2025-$4.7M
Mar 2025-$7.5M
Jun 2024-$7.1M
Mar 2024-$6.9M
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 20251.70x
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026n/a
Mar 20264.00x
Dec 20251.70x
Sep 2025n/a
Jun 20251.96x
Mar 20251.42x
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.67x
TTM operating cash flow over long-term debt only, 2026-06-30
History
FY Dec 2025-0.90x
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026-0.67x
Mar 2026-0.70x
Dec 2025-0.90x
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-657.8%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-155.3%
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026-657.8%
Mar 2026-268.9%
Dec 2025-155.3%
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-77.8%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-54.7%
FY Dec 2024-485.5%
FY Dec 2023n/a
Jun 2026-77.8%
Mar 2026-60.4%
Dec 2025-54.7%
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024-485.5%
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-69.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025-57.6%
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026-69.2%
Mar 2026-59.4%
Dec 2025-57.6%
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$20.0M
market value at close 2026-10-09 on 2026-08-10 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
History
FY Dec 2025$26.0M
FY Dec 2024$32.9M
FY Dec 2023n/a
Jun 2026$31.6M
Mar 2026$35.5M
Dec 2025$26.0M
Sep 2025$46.4M
Jun 2025$28.7M
Mar 2025$17.1M
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-573.9%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025-88.0%
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026-114.4%
Mar 2026-62.5%
Dec 2025-88.0%
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

ADGM Stock Sonar score 4/7 axes

Find similar shapesCompare

ADGM ranks highest on financial health (37th percentile) and profitability (18th), and lowest on growth (1st), among Medical Devices peers.

Profitability
18
Inputs
  • Return on equity-657.8% · 4 pct, sector of 182
  • Return on assets-77.8% · 23 pct, sector of 213
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-69.2% · 27 pct, sector of 188
Financial health
37
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.67x · 37 pct, sector of 150
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
11
Inputs
  • Short interest, % of float+15.2% · 8 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+22.5% · 14 pct, sector of 198
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-100.0% year over year
the lowest in Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.2% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
more than 69% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ADGM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-94.5%12M
-94%-63%-31%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-12-12 · Usen Todd bought $226.0K2025-12-16 · Kaster Deborah bought $18.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

Adagio Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Adagio Medical Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
Kaster Deborah
Chief Financial Officer
BUY
2025-12-16
15,000
$18.0K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 15,000 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Chief Financial Officer Kaster Deborah bought about $18.0K of ADGM on the open market on Dec 16, 2025; 1 other insider bought within 30 days.
Usen Todd
Chief Executive Officer
BUY
2025-12-12
207,315
$226.0K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 207,315 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Chief Executive Officer Usen Todd bought about $226.0K of ADGM on the open market on Dec 12, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
2 transactions on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns ADGM: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ADGM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ADGM planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$0n/a$300.0K
Operating income$-21.9Mn/a$-27.9M
Net income$-25.1Mn/a$-36.6M
EPS (diluted)-1.51n/a-48.16
Operating cash flow$-19.0Mn/a$-25.7M
Cash$17.1M$20.6M$1.4M
Long-term debt$21.0M$17.2M$38.3M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies